Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (306)	12/18/1997 8:58:00 PM
From: 5,17,37,5,101,...	Respond to of 756

Randy, I spoke to Robert Jaffee, IR, today. 1)He confirmed all insider purchases listed in the Roader post (sorry Roader) and informed me of another: 2500...11/97...Andrews...Director (I guess a new director) Cited insider accumulation as indication of confidence and high morale at company HQ but he couldn't speak for employees working across the world in their many factories and divisions. [I guess that means there is no communication. Do they use telephones? Do they even know each other?] 2)Paxene a) Manage. is "very concerned" about the K-S orphan status of Taxol. b) No other filings have yet been made here in US. c) FDA has not requested any further information. Management is waiting. This is all they can do. d) Paxene has not been approved anywhere else yet; "no response" to ANY further questions on this topic due to intense competition with BM-S. e) He mentioned that it will difficult for anyone to make a lot of money on these paclitaxel drugs because of the competition: BM-S, Immunex,Ivax, et al. 3)He directed me to most recent 10K for a list of drugs currently working on, i.e. no comment. 4) Ivax has not been fully divested of Personal Care or Specialty Chem divisions. He was vague about what remains, I believe because he was uninformed. He described them as good businesses. I told him about the loss incurred by the Personal Care division. He seemed surprised. 5) The three board members who jumped ship during the last Q did so for "personal reasons." I told him that was unusual. He felt it was within acceptable limits. A canned response here was expected. Jaffee of course did not want to divulge information that might jeopardize current efforts; however, I really expected more inform. regarding the discontinued assets. I think we will have to wait until the 10Q. IMHO, good news will arise from efforts in 2d or 3 above. Sorry I don't really have much new here, Jackson

To: flickerful who wrote (306)	12/18/1997 9:02:00 PM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

The entire paclitaxel topic is extremely byzantine. I really give up trying to understand it.